Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Immunol. 2011 Jun 22;187(3):1113–1119. doi: 10.4049/jimmunol.1100056

Figure 4. Blockade of PDL1: B7.1 pathway accelerated cardiac allograft rejection in PD1 and B7.2 deficient recipients.

Figure 4

(A) bm12 hearts were transplanted into PD1KO recipients and the recipients were treated with 2H11 anti-PDL1 mAb. The survival time of cardiac allografts was significantly shortened as compared to controls. (B) bm12 hearts were transplanted into B7.2-deficient B6 recipients and the recipients treated with 2H11. Bm12 cardiac grafts transplanted into B6 B7.2-deficient recipients had a median survival time of greater than 56 days, while 2H11 precipitated allograft loss. N= 6 for each group.